Svetlana Pyatigorskaya
Family · Brooklyn, NYNPI 1063509081
Payments from drug & device makers
Across 156 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$967
- Ardelyx, Inc.$390
- AstraZeneca$372
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$311
- Novartis$242
- Amgen$208
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,44097%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $967 |
| Ardelyx, Inc. | 9 | $390 |
| AstraZeneca | 16 | $372 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $311 |
| Novartis | 10 | $242 |
| Amgen | 10 | $208 |
| Pfizer | 7 | $147 |
| Amarin Pharma, Inc. | 7 | $143 |
| Otsuka America Pharmaceutical, Inc. | 5 | $107 |
| Astellas Pharma US Inc | 1 | $100 |
| Merck | 5 | $97 |
| Ironwood Pharmaceuticals, Inc | 4 | $89 |
| Lilly USA, LLC | 4 | $77 |
| Boehringer Ingelheim | 3 | $70 |
| Shield Therapeutics Inc | 2 | $48 |
| Scilex Pharmaceuticals Inc. | 2 | $45 |
| Vivus LLC | 2 | $43 |
| Almatica Pharma LLC | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,540 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 415 | $601,409 |
| ZenpepLipase/Protease/Amylase | 196 | $281,991 |
| LinzessLinaclotide | 483 | $270,588 |
| Nurtec OdtRimegepant Sulfate | 106 | $165,186 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 119 | $144,415 |
| Diclofenac Sodium | 295 | $127,113 |
| MounjaroTirzepatide | 110 | $121,357 |
| VascepaIcosapent Ethyl | 315 | $103,246 |
| EntrestoSacubitril/Valsartan | 134 | $90,890 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 132 | $82,366 |
| EliquisApixaban | 126 | $82,145 |
| OzempicSemaglutide | 72 | $68,917 |
| ZtlidoLidocaine | 152 | $66,688 |
| FarxigaDapagliflozin Propanediol | 103 | $62,170 |
| HorizantGabapentin Enacarbil | 115 | $56,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis, Ubrelvy, Namzaric | $967 | $968,0991,024 claims |
| PfizerNurtec Odt, Eliquis, Zavzpret | $147 | $298,226258 claims |
| Lilly USA, LLCMounjaro | $77 | $121,357110 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $372 | $111,829180 claims |
| MerckJanumet, Januvia, Steglujan | $97 | $99,130162 claims |
| NovartisEntresto | $242 | $90,890134 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $45 | $66,688152 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $70 | $65,664120 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $48,787113 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $311 | $34,41813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.
Other family in Brooklyn
- Seida VelijaBrooklyn$62K
- Ofiong OkonBrooklyn$44K
- Irina FainbergBrooklyn$23K
- Susan WeissBrooklyn$22K
- Razan AlawadhiBrooklyn$21K
- Christina LaoBrooklyn$20K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.